DXR vs. DRIO, LUCD, LNSR, XAIR, CTSO, CTCX, APYX, ICCM, NSPR, and MODD
Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include DarioHealth (DRIO), Lucid Diagnostics (LUCD), LENSAR (LNSR), Beyond Air (XAIR), Cytosorbents (CTSO), Carmell (CTCX), Apyx Medical (APYX), IceCure Medical (ICCM), InspireMD (NSPR), and Modular Medical (MODD). These companies are all part of the "surgical & medical instruments" industry.
DarioHealth (NASDAQ:DRIO) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
Daxor has a net margin of 0.00% compared to Daxor's net margin of -282.38%. DarioHealth's return on equity of 0.00% beat Daxor's return on equity.
DarioHealth presently has a consensus target price of $4.05, indicating a potential upside of 113.16%. Given Daxor's higher probable upside, equities analysts clearly believe DarioHealth is more favorable than Daxor.
33.4% of DarioHealth shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 15.7% of DarioHealth shares are held by insiders. Comparatively, 60.6% of Daxor shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Daxor has lower revenue, but higher earnings than DarioHealth.
In the previous week, DarioHealth had 9 more articles in the media than Daxor. MarketBeat recorded 9 mentions for DarioHealth and 0 mentions for Daxor. Daxor's average media sentiment score of 0.39 beat DarioHealth's score of 0.00 indicating that DarioHealth is being referred to more favorably in the media.
DarioHealth received 238 more outperform votes than Daxor when rated by MarketBeat users.
DarioHealth has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500.
Summary
DarioHealth beats Daxor on 8 of the 13 factors compared between the two stocks.
Get Daxor News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
